Cybin Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary psychedelic-based therapies to address mental health conditions. Founded in 2019 and headquartered in Toronto, Ontario, the company is pioneering novel formulations and delivery methods for psilocybin and other psychoactive compounds. Cybin’s mission centers on harnessing the therapeutic potential of psychedelics to treat depression, anxiety, post-traumatic stress disorder (PTSD) and various forms of substance use disorder.
The core of Cybin’s pipeline comprises deuterated psilocybin analogs and next-generation tryptamine (NTT) compounds designed for optimized pharmacokinetic profiles. The company has developed a suite of proprietary drug delivery platforms—including oral thin films, intranasal sprays and sublingual tablets—that aim to improve patient experience, dose control and safety. Cybin’s preclinical and early-stage clinical programs explore both mono-therapeutic and adjunctive approaches, with studies conducted under Investigational New Drug (IND) applications in key regulatory jurisdictions.
Cybin maintains research and development facilities in Canada and the United States, complemented by strategic partnerships with leading academic institutions and contract research organizations. Through collaborative agreements, the company is actively advancing multi-site clinical trials to evaluate efficacy, tolerability and long-term outcomes. Cybin’s global footprint extends to Europe and Latin America via research collaborations and licensing discussions as it seeks to establish a scalable supply chain and regulatory pathway for its products.
Under the leadership of President and Chief Executive Officer Doug Drysdale, Cybin’s management team combines expertise in drug development, regulatory affairs and life sciences commercialization. The company’s board and scientific advisory committee include seasoned veterans in neuroscience, psychiatric medicine and pharmaceutical manufacturing. Cybin continues to build a robust intellectual property portfolio and to engage with regulatory agencies to advance its vision of bringing innovative psychedelic therapies to patients in need.
AI Generated. May Contain Errors.
